Document is current

Article History

Received: 7 April 2024

Accepted: 23 July 2024

First Online: 9 August 2024

Declarations

:

: Yoshiya Tanaka has received speaking fees and/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers, Pfizer, and Taiho, and received research grants from Mitsubishi-Tanabe, Eisai, Chugai, and Taisho. Shingo Nakayamada has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers, AstraZeneca, Pfizer, GlaxoSmithKline, Astellas, Asahi-kasei, Sanofi, Abbvie, Eisai, Chugai, Gilead, and Boehringer Ingelheim, and has received research grants from Mitsubishi-Tanabe. The authors declare no conflicts of interest. Yusuke Miyazaki has received consulting fees, speaking fees, and/or honoraria from Eli Lilly and has received research grants from GlaxoSmithKline. Yoshiya Tanaka is an Editorial Board member of <i>Rheumatology and Therapy</i>. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Naoaki Ohkubo, Shunsuke Fukuyo, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Yasuyuki Todoroki, Hiroko Miyata, Atsushi Nagayasu, Masashi Funada, Hiroki Kobayashi, Hidenori Sakai, Shumpei Kosaka, Satsuki Matsunaga, Yukiko Tomoyose, Hirotsugu Nohara have nothing to disclose.

: The study complied with the Declaration of Helsinki and the research protocol was approved by the Ethics Committee of the School of Medicine, University of Occupational and Environmental Health, Japan (UOEHCRB21-068). In addition, informed consent was obtained appropriately by the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Health, Labor, and Welfare in April 2015.